Comparative Pharmacology
Head-to-head clinical analysis: CASPOFUNGIN ACETATE versus MYCAMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CASPOFUNGIN ACETATE versus MYCAMINE.
CASPOFUNGIN ACETATE vs MYCAMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Caspofungin acetate is an echinocandin antifungal that inhibits the synthesis of 1,3-beta-D-glucan, an essential component of the fungal cell wall, by noncompetitively inhibiting the enzyme 1,3-beta-D-glucan synthase. This leads to osmotic instability and cell lysis, primarily against Candida and Aspergillus species.
Micafungin is an echinocandin antifungal that inhibits the synthesis of 1,3-β-D-glucan, an essential component of the fungal cell wall, leading to osmotic instability and cell death.
Adults: 70 mg IV loading dose on day 1, then 50 mg IV once daily.
100 mg IV once daily for invasive candidiasis; 150 mg IV once daily for esophageal candidiasis.
None Documented
None Documented
Terminal elimination half-life ~9-11 hours in adults, with a prolonged terminal phase (beta half-life 40-50 hours) due to slow tissue distribution and redistribution. Clinically, dosing interval is 24 hours.
Terminal elimination half-life is approximately 14.3 hours (range 11–17 hours) in healthy adults. In pediatric patients, half-life is shorter (approximately 10–12 hours). Clinically, steady state is achieved by day 3 with daily dosing.
Primarily hepatic: slow metabolism with subsequent biliary and fecal excretion. ~35% of administered dose excreted in feces and ~41% in urine over 27 days, with <2% unchanged in urine. Minimal renal excretion as unchanged drug.
Primarily excreted unchanged via feces (approximately 28%) and to a lesser extent via urine (approximately 15%). Overall, elimination is primarily non-renal with biliary/fecal excretion as the major route. Less than 1% is excreted as metabolites.
Category A/B
Category C
Echinocandin Antifungal
Echinocandin Antifungal